LOS ANGELES, CA / ACCESSWIRE / March 20, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Investors, who purchased or otherwise acquired shares between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On January 6, 2017, the Wall Street Journal announced DaVita had received subpoenas from federal prosecutors for “the production of information related to charitable premium assistance” concerning the Company’s relationship with the American Kidney Fund, a charity that offers financial help for patients undergoing kidney dialysis. When this information was released to the public, the value of DaVita stock fell, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457710

IRVINE, CA / ACCESSWIRE / March 20, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against OneMain Holdings Inc. (“OneMain” or the “Company”) (NYSE: OMF). Investors, who purchased or otherwise acquired OneMain shares between March 3, 2015, and November 7, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of OneMain during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

OneMain designs, markets, and sells financial products through its subsidiaries. On November 7, 2016, OneMain revealed unsatisfactory third quarter financial results. When this information was revealed to the investing public, the value of OneMain declined, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457711

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA) and certain of its officers, on behalf of a class who purchased DaVita securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/dva.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore, DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting; and (5) consequently, DaVita’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. Once true details were made known to the investing public, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/dva, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in DaVita, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454440

LOS ANGELES, CA / ACCESSWIRE / March 20, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ: EGLT). Investors, who purchased or otherwise acquired Egalet shares between December 15, 2015 and January 9, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The investigation is centered on whether Egalet and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On January 9, 2017, Egalet issued a statement regarding approval for its product Arymo ER. The same day, the U.S. Federal Drug Administration stated that another product, MorphaBond, “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Due to MorphaBond’s exclusivity within this market, “no other single-entity extended-release morphine product submitted in an abbreviated new drug application or 505(b)(2) application can be approved for that use at this time.”

When this information was revealed to the investing public, the value of Egalet declined, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457705

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ: EGLT) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Egalet securities between December 15, 2015, and January 9, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/eglt.

The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose material adverse information about its lead product, ARYMO ER, and the likelihood that it would receive oral abuse-deterrent labeling.

On January 9, 2017, Egalet released a statement announcing the approval of its product Arymo ER. Later that day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Following this news, Egalet stock dropped, thus damaging investors.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/eglt, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Egalet, you have until March
28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 453862

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Omgea Protein Corp. (“Omega” or the “Company”) (NYSE: OME) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Omgea securities between August 3, 2016 and March 1, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/ome.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) the SEC is requesting information in connection with an investigation relating to Omega’s subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees; (2) it is possible that the foregoing matter could result in a material adverse effect on Omega’s business, reputation, results of operation and financial condition; and (3) consequently, Defendants’ statements about Omega’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.

On March 1, 2017, post-market, Omega revealed that it had received a subpoena from the U.S. Securities and Exchange Commission seeking information about an investigation of Omega subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees. Following this news, Omega stock dropped as much as $5.86 per share, or 22.32%, during intraday trading on March 2, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/ome, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Omega you have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456516

IRVINE, CA / ACCESSWIRE / March 20, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Vista Outdoor, Inc. (“Vista” or the “Company”) (NYSE: VSTO). Investors, who purchased or otherwise acquired Vista shares between August 11, 2016, and January 13, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of Vista during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On January 12, 2017, Vista revealed that it expects a material asset impairment charge (approximately $400 – $450 million) due to its Hunting and Shooting Accessories reporting unit during the third quarter of the 2017 fiscal year. When this news was announced, the value of Vista fell over 21% that day. On January 13, 2017, Vista stated that the President of its Outdoor Products segment, in which the Hunting and Shooting Accessories unit belongs, had left his position.

When this information was revealed to the investing public, the value of Vista declined, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457709

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of SCYNEXIS, Inc. (“SCYNEXIS”) (NASDAQ: SCYX) (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information, go to: http://www.zlk.com/pslra/scynexis-inc, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product, SCY-078, posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.

On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.

If you suffered a loss in SCYNEXIS, you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 457707

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Caterpillar Inc. (“Caterpillar” or the “Company”) (NYSE: CAT) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Caterpillar securities between February 19, 2013 and March 1, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/cat.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Caterpillar unlawfully used foreign subsidiaries to avoid paying billions of dollars in U.S. taxes; (2) discovery of the foregoing conduct would subject the Company to heightened regulatory scrutiny and potential criminal sanctions; and (3) consequently, Caterpillar’s public statements were materially false and misleading at all relevant times.

On March 2, 2017, law enforcement officials executing a search warrant searched the Caterpillar’s facilities in Peoria, Illinois. The Peoria Journal Star narrated that some of the officials wearing Internal Revenue Service logo jackets were seen entering the company’s headquarters. Following this news, Caterpillar stock has dropped $4.22 per share, or 4.28%, to close at $94.36 per share on March 2, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/cat, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Caterpillar, you have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456511

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against RH (formerly Restoration Hardware Holdings, Inc.) (“RH” or the “Company”) (NYSE: RH) and certain of its officers, on behalf of a class who purchased RH securities between March 26, 2015 and June 8, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/rh.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and misleading statements, specifically its earnings forecasts based on a new product line, RH Modern. The complaint further alleges that RH misrepresented and concealed problems surrounding the launch of RH Modern, including inventory shortages, shipping delays, and poor construction quality.

On June 8, 2016, RH revealed its financial and operating results for the first quarter of 2016 and significantly lessened its earnings guidance for fiscal year 2016, noting “accommodations largely due to…production delays” in RH’s new product line, RH Modern, which the Company had previously touted as “the most important and significant new home furnishings business to be launched in the last 15 or 20 years.” Following this news, RH stock dropped $7.66, or 21.24%, to close at $28.41 on June 9, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: www.bgandg.com/rh, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in RH, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454514